2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Serologic Tests, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4071 M-protein kinetics via clonotypic mass spectrometry following BCMA-directed CAR T cell therapy

Dalton Hill, MD, Margaret Minett, N/A2, Julie Fortier, PhD3, Mark Fiala, MSW, PhD4, Sarah Kelley5, Mark Zaydman, MD, PhD6, Mark Schroeder, MD, MSCI7, Keith Stockerl-Goldstein, MD8, Ravi Vij, MD, MBA9, Abir Khaled, PhD10, Zac McDonald, PhD11, Liqiang Yang, PhD12, Michael J. Slade, MD, MSCI13
1 Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
2 Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
3 Washington University in St. Louis, St. Louis, Missouri, United States
4 Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
5 Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
6 Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
7 Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
8 Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
9 Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
10 Rapid Novor, Kitchener, Ontario, Canada
11 Rapid Novor, Kitchener, Ontario, Canada
12 Rapid Novor, Kitchener, Ontario, Canada
13 Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States

Background

As chimeric antigen receptor (CAR) T cell therapy becomes more prevalent in relapsed multiple myeloma (MM) treatment, disease monitoring post-CAR T with a highly sensitive, non-invasive assay remains an unmet need. Individualized M-protein quantification using clonotypic mass spectrometry (CT-MS) may provide a more comprehensive understanding of disease kinetics over time while offering a less invasive approach to post–CAR T disease monitoring than current marrow-based minimal residual disease (MRD) monitoring. Thus, we aim to describe post-CAR T M-protein kinetics using CT-MS and identify disease kinetics that may be predictive of post-CAR T outcomes.

Methods

Patients receiving BCMA-directed CAR T therapy for relapsed MM consented to our MM banking protocol underwent serial serum collection for CT-MS analysis using the EasyM assay (Rapid Novor, Kitchener, ON). Clonotype generation generally requires a sample with M-protein ≥0.2 g/dL by serum protein electrophoresis or >20 mg/dL for free light chain (FLC). Samples were collected at day +30, +100, and +365 post-CAR T therapy, as well as other select time points (including relapse). Baseline and follow-up samples were analyzed by Rapid Novor, who were blinded to clinical data. Percent residual and absolute CT-MS were used as a measure of dynamic M-protein response. M-proteins were classified as long half-life (LHL) (IgG) versus short half-life (SHL) (IgA/IgD/FLC). Marrow-based MRD was analyzed using clonoSEQ at a threshold of >10-6 MM cells/cells measured.

Results

Baseline clonotype by CT-MS was established in all 52 patients who met the study criteria, including 4 patients with M-protein <0.2 g/dL. Median age was 67 years (range: 43 – 80). 94% received cilta-cel.  Median time from diagnosis to CAR T cell was 7.2 years (range: 0.7 – 21.7) and median lines of therapy was 4. M-protein isotypes were IgG (n = 34), IgA (9), FLC (8) and IgD (1).

172 follow-up samples were analyzed, most commonly at day +30 (n = 48), +100 (39), 1 year (33), 2 years (9) and relapse (8). M-protein isotype was highly correlated with achieving undetectable M-protein by CT-MS (SHL vs. LHL: 49% vs. 25%) at all time points. Undetectable M-protein in SHL patients occurred as early as 30 days (17%), was achieved in the majority of patients at day +100 (54%) and was common by 1 year in patients still in remission (92%). Undetectable M-protein for LHL patients was never observed prior to 1 year but increased in frequency with duration post-CAR T (1y: 20%, 2y: 50%, 3y: 75%, 4y: 100%, p < 0.001). No statistically significant absolute or relative CT-MS threshold at day +30, +100 or +365 was identified correlating with progression-free survival.

In patients with available MRD data, 14% (6/43), 9% (4/43), and 18% (5/28) were MRD+ at day +30, +100, and +365. MRD+ patients had numerically higher residual M-protein than MRD- patients at day +30 (median % of baseline M-protein by CT-MS: 62.94% vs. 11.06%, p = 0.054) and day +365 (0.29% vs. 0.17% p = 0.405).

The median follow-up was 565 days (range: 116 – 1348). During follow-up, 13 patients relapsed, with 10 at or prior to 1 year. All relapsing patients had at least one pre-relapse CT-MS sample (median: 191 days, range: 36 – 714), with 8 patients (62%) having detectable M-protein at that time point. All patients without detectable disease on pre-relapse CT-MS had SHL M-proteins, with samples drawn a median of 217 days prior to relapse (range: 55 – 714). Two relapsing patients (15%) had relative increases on pre-relapse CT-MS. 7 relapsing patients had samples drawn at or near relapse (median time: 2 days, range: -26 - +43).  All were CT-MS positive at relapse (median of 44.05%, range: 1.7 – 369.0%) and higher than the pre-relapse CT-MS (median increase: 18.3%, range: 1.7 – 237.3%).

Conclusion

Our findings illustrate the utility and challenges of highly sensitive CT-MS monitoring following CAR T therapy. Achieving “undetectable” CT-MS is highly dependent on M-protein half-life, which is abnormally prolonged for IgG. CT-MS is highly sensitive for relapse, with detectable and increasing M-protein in 100% of relapse samples tested. Our study suggests CT-MS should be monitored frequently (every 1 – 3 months) given the lack of lead time increase in CT-MS prior to relapse. Larger cohorts with longer follow-up are needed for isotype-specific kinetic parameters and thresholds for predictive use of CT-MS, including prognosis and correlation with marrow-based MRD.

Dalton Hill, MD: No relevant conflicts of interest to declare.